



ASX Release

6 March 2019

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Monsoon Communications
Rudi Michelson
+61 3 9620 3333
rudym@monsoon.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTCQB): ZLDAF

Ordinary Shares:
755,341,934

Options:
85,700,000

Zelda Secures Australian Patent For Novel Prognostic Marker for Breast Cancer

- Zelda awarded patent for a novel prognostic biomarker for breast cancer
- Builds on Zelda's world-class intellectual property portfolio for medicinal cannabis and cancer therapy
- Prognostic marker helps predict patient survival and the probability of disease recurrence
- Complements Zelda's ongoing programmes to develop cannabis-based therapies for cancer
- Patent provides protection until 2038

Zelda Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce the grant of a new patent in Australia covering a novel method to predict patient disease-free survival. The patent provides protection until 2038.

The patent (AU2017346940A) entitled "Prognostic method and kits useful in said method" details a method for detecting levels of expression of a novel receptor complex containing HER2 and CB2. HER2 is a well-recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system. Together they form a novel receptor complex that represents a prognostic marker for HER2 positive breast cancer.

Zelda's Managing Director, Dr Richard Hopkins commented *"We're delighted with the allowance of this patent, which supports Zelda's strategy of building a world-class intellectual property portfolio and the development of cannabis-based products. Further news is expected as this patent family progresses through the international examination phase.*

I'd also like to acknowledge the work of Professor Cristina Sanchez and her team who generated the data that supported this patent. This work was recently published in the prestigious peer-reviewed Proceedings of the National Academy of Sciences. This outcome highlights the benefit of Zelda's approach of partnering with world-leading cannabis researchers.

Importantly, Professor Sanchez's discovery of a novel prognostic biomarker, will complement our ongoing efforts develop to cannabis-based medicines to treat breast cancer. "

Tim Slate
Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd is an Australian-based bio-pharmaceutical company developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company is undertaking:

- A **human clinical trial programme** focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

The company conducts this work in partnership with world-leading researchers and organisations including Complutense University in Madrid, Spain; Curtin University in Perth, Western Australia; the Telethon Kids Institute in Perth; the University of Western Australia, in Perth; St. Vincent's Hospital in Melbourne, Australia; and the Children's Hospital of Philadelphia (CHOP) in the United States

Zelda has also formed a strategic partnership with European medicinal cannabis group HAPA Medical BV, to access HAPA's EU-GMP grade manufacturing capabilities and accessing its German distribution network providing a credible and rapid path to commercialisation for successful clinically validated formulations.